Iovance Biotherapeutics Announces Conference Presentations in 2025

Author: Kelly Martin Updated: 08-29-2025 08:47 AM

Iovance Biotherapeutics Announces Upcoming Conference Appearances

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering biotechnology firm dedicated to advancing treatments through innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies, has revealed that its senior executive team will be showcasing their expertise at several prestigious conferences in the near future.

Presentation Schedule

The first major event on their calendar is the 2025 Wells Fargo Healthcare Conference, where the leadership will engage in a fireside chat on September 5, 2025, at 8:00 a.m. ET. Following this, the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, featuring a presentation scheduled for September 9, 2025, at 11:00 a.m. ET.

Live Webcasts Availability

For those who are unable to attend these presentations in person, live and archived webcasts will be accessible online, providing insights into the company’s advancements and strategies. This access is crucial for investors and interested parties wishing to stay informed about Iovance's progress in the biotechnology field.

About Iovance Biotherapeutics

Iovance Biotherapeutics is on a mission to lead the global charge in innovating, developing, and distributing TIL therapies for cancer patients. With a commitment to harnessing the robust capabilities of the human immune system, the company seeks to create groundbreaking cancer treatments tailored to the diverse characteristics of tumors in each individual.

Innovative Treatment Technologies

The Iovance TIL platform remains at the forefront of clinical advancements, presenting promising results across a variety of solid tumors. Among its notable achievements is Amtagvi, recognized as the first FDA-approved T cell therapy specifically for solid tumors. Iovance strives to continue its path of innovation not just in TIL therapies but also in exploring gene-edited cell therapies that hold the potential to significantly enhance and extend patients' lives.

Contact Information for Inquiries

For further information or queries, interested parties can reach out via the following channels:

Investors:
IR@iovance.com
Phone: 650-260-7120 ext. 150

Media:
PR@iovance.com
Phone: 650-260-7120 ext. 150

Frequently Asked Questions

What is Iovance Biotherapeutics known for?

Iovance Biotherapeutics specializes in innovative cancer treatments utilizing tumor infiltrating lymphocyte (TIL) therapies.

When are the upcoming conferences?

Iovance is scheduled to present at the Wells Fargo Healthcare Conference on September 5 and the H.C. Wainwright Annual Conference on September 9, 2025.

How can I access the webcasts?

Webcasts of the presentations will be available live and archived online for those interested in Iovance's developments.

What are TIL therapies?

TIL therapies involve extracting and expanding the immune cells that infiltrate tumors, then reinfusing them to help combat cancer.

How can I contact Iovance for more information?

For inquiries, individuals can reach the Investor Relations or Media departments via the email addresses provided above.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.